Loading stock data…
$4.18+0.11 (+2.57%)
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests.
Myriad Genetics, Inc. in the Healthcare sector is trading at $4.18 with a market capitalization of $290M. Wall Street consensus targets $4.11 (8 analysts), implying a -1.7% move over the next 12 months. The stock is currently 51% below its 52-week high of $8.59, remaining 10.0% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 30/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $190.70M↓ | $200.40M↓ | $209.80M↑ | $205.70M↓ | $213.10M |
| Gross Profit | $127.00M↓ | $137.60M↓ | $146.80M↑ | $143.80M↓ | $151.80M |
| Operating Income | -$38.90M↓ | -$25.30M↓ | -$3.00M↑ | -$23.30M↓ | -$12.50M |
| Net Income | -$43.20M↓ | -$34.10M↓ | -$7.90M↑ | -$27.40M↑ | -$330.50M |
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test,...